BioCentury | Dec 23, 2020
Product Development

Dec. 21-23 Quick Takes: readouts for Genentech, Rhythm, ChemoCentryx and BMS

...trials to treat diabetic macular edema. Detailed data on the bispecific mAb against VEGF-A and ANG2...
...The PD-1 inhibitor missed the trial's other primary endpoint of progression-free survival in September 2019.TARGETSANG2 (ANGPT2...
BioCentury | Dec 16, 2020
Deals

Dec. 15 Quick Takes: Singlera raises $150M for cancer dx; plus AnGes-Emendo, Entresto, vTv and Unity

Cancer screening play Singlera raises megaroundSinglera Genomics Inc. raised $150 million in a series B round led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment. Fellow new...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

OncoImmune raises $56M series BOncoImmune Inc. raised $56 million in a series B round co-led by HM Capital and an undisclosed investor. Also participating were fellow new investors GBA Fund and GF Xinde, and existing...
BioCentury | Aug 31, 2020
Deals

Three years after spinout, Ionis brings back Akcea in $500M acquisition

Three years after Ionis spun out its Akcea unit in an IPO, and nearly a year after the parent company installed a new CEO at the subsidiary, Ionis has chosen to retake full ownership of...
BioCentury | Aug 13, 2020
Regulation

Aug. 12 Quick Takes: Approvals for DMD, acute pain; plus Priority Review for Fabry, hypercholesterolemia therapies and more

FDA approves a second targeted DMD therapyNS Pharma Inc.’s Viltepso viltolarsen received accelerated approval from FDA to treat Duchenne muscular dystrophy in patients amenable to exon 53 skipping. Vyondys golodirsen from Sarepta Therapeutics Inc. (NASDAQ:SRPT) was the...
BioCentury | Jul 8, 2020
Finance

Crossovers pile into $110M series B as Vor heads into the clinic

Vor's $110 million series B round gives the hematopoietic stem cell play enough fuel to keep its financing options open as it advances its lead program into the clinic. RA Capital led the round, which...
BioCentury | Jun 11, 2020
Finance

Insiders lead, crossovers join in gene editing play Verve’s $63M round

When gene editing company Verve went out seeking new investors for its latest round of funding, existing shareholder GV decided it would rather lead the round itself. GV and existing investors Arch Venture Partners, F-Prime...
BioCentury | May 26, 2020
Distillery Therapeutics

DNA-based HGF/SF mimetic for hepatitis

DISEASE CATEGORY: Infectious disease INDICATION: Hepatitis An oligonucleotide-based mimetic of HGF/SF, a growth factor that can stimulate liver regeneration, could treat hepatitis. The HGS/SF mimetic comprises a dimer of two 50-nucleotide single-stranded DNA molecules. In...
BioCentury | Apr 11, 2020
Product Development

COVID-19 roundup: Lilly joins NIH’s adaptive trial; plus Foresee, Congress, ASCO, BMS, Otsuka, EC, Terumo-Marker

...plans to start this month a U.S. Phase II trial of LY3127804, a mAb against ANG2...
...analysis of the coronavirus crisis can be found at https://www.biocentury.com/coronavirus . Targets ANG2 (ANGPT2) - Angiopoietin 2...
BioCentury | Mar 11, 2020
Product Development

COVID-19 patients on Ascletis’ HCV drug discharged; plus Mesoblast allogeneic stem cells for COVID-19, Acceleron, Bridge-Atomwise, Cellectis and Abpro

...covers ABP-100, a cancer therapy targeting HER2 and CD3; and ABP-201, which targets VEGF and ANG2...
Items per page:
1 - 10 of 340